McCullough Robertson’s Equity Capital Markets team has successfully advised clinical-stage biotech company Radiopharm Theranostics Limited (ASX: RAD) on its two-tranche placement to raise up to $35 million, together with a $5 million share purchase plan, primarily to fund the next stage of the clinical trials of its innovative radiopharmaceutical products for cancer diagnosis and treatment.

The placement attracted strong investor interest and included a strategic investment of $7.6 million by NASDAQ-listed Lantheus Holdings, Inc. subject to shareholder approval at an extraordinary general meeting. This capital raising strengthens Radiopharm’s funding position, supports the advancement of its clinical pipeline, and builds strategic partnerships in a competitive biotech sector.

Our Life Sciences specialists have acted for Radiopharm since its IPO. It was a pleasure to assist the company on this successful capital raising, supporting its ongoing growth strategy.